| |
| |
|
| Insider
Information: |
Brown Morgan R |
| Relationship: |
EVP and CFO |
| City: |
Salt Lake City |
| State: |
UT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
194,504 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$55,434 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
194,504 |
|
|
| Total
Value |
$55,434 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
NPS Pharmaceuticals Inc |
NPSP |
Vice President, Finance |
2005-02-01 |
0 |
2004-08-02 |
0 |
Premium* |
|
|
Lipocine Inc |
LPCN |
EVP and CFO |
2020-12-16 |
194,504 |
2013-09-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LPCN |
Lipocine Inc |
EVP and CFO |
• – – |
2020-12-16 |
4 |
AS |
$1.35 |
$11,390 |
D/D |
(8,437) |
194,504 |
0 |
% |
|
| LPCN |
Lipocine Inc |
EVP and CFO |
• – – |
2020-12-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,125 |
202,941 |
0 |
- |
|
| LPCN |
Lipocine Inc |
Chief Financial Officer |
• – – |
2020-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
70,754 |
174,816 |
0 |
- |
|
| LPCN |
Lipocine Inc |
Chief Financial Officer |
• – – |
2020-12-04 |
4 |
AS |
$1.57 |
$27,024 |
D/D |
(17,250) |
104,062 |
0 |
% |
|
| LPCN |
Lipocine Inc |
Chief Financial Officer |
• – – |
2020-12-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
57,500 |
121,312 |
0 |
- |
|
| LPCN |
Lipocine Inc |
EVP and Chief Financial Office |
• – – |
2019-12-04 |
4 |
AS |
$0.41 |
$7,076 |
D/D |
(17,250) |
63,812 |
0 |
- |
|
| LPCN |
Lipocine Inc |
EVP and Chief Financial Office |
• – – |
2019-12-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
57,500 |
81,062 |
0 |
- |
|
| LPCN |
Lipocine Inc |
EVP and CFO |
• – – |
2017-12-29 |
4 |
AS |
$3.47 |
$9,773 |
D/D |
(2,813) |
23,562 |
0 |
- |
|
| LPCN |
Lipocine Inc |
EVP and CFO |
• – – |
2017-12-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
26,375 |
0 |
- |
|
| LPCN |
Lipocine Inc |
EVP and CFO |
• – – |
2013-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Vice President, Finance |
• – – |
2005-02-01 |
4 |
AS |
$16.19 |
$14,540 |
D/D |
(898) |
0 |
|
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Vice President, Finance |
• – – |
2005-01-31 |
4 |
A |
$14.03 |
$12,594 |
D/D |
898 |
898 |
|
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Vice President, Finance |
• – – |
2004-08-03 |
4 |
AS |
$17.95 |
$6,247 |
D/D |
(348) |
0 |
|
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Vice President, Finance |
• – – |
2004-08-02 |
4 |
A |
$15.57 |
$5,419 |
D/D |
348 |
348 |
|
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Vice President, Finance |
• – – |
2004-02-03 |
4 |
AS |
$32.99 |
$21,476 |
D/D |
(651) |
0 |
|
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
Vice President, Finance |
• – – |
2004-02-02 |
4 |
A |
$17.48 |
$11,382 |
D/D |
651 |
651 |
|
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
